“The overall evidence from clinical trials and meta-analyses suggests that device-guided slow breathing can significantly lower BP. There are no known contraindications to the use of the device, and no adverse effects have been noted.[104] Unfortunately, the device currently costs in excess of $200 in the United States; however, it has recently been included on the British National Health Service’s Drug Tariff (Part IX), which makes its cost reimbursable if prescribed by a physician. Specific recommendations for use are outlined elsewhere[110] and by the manufacturer (https://www.resperate.com). Another limitation is that device-guided slow breathing has not been directly compared with other forms of regulated breathing such as pranayama. Hence, it remains unknown whether paced slow breathing can be taught and effectively used to lower BP over the long term without the use of a device. According to trial evidence, 15-minute sessions of device-guided slow breathing need to be performed at least 3 to 4 times per week to reduce BP. It has been suggested that more frequent use may lead to greater BP lowering; however further evidence is required in this regard. There have been no trials longer than 8 to 9 weeks’ duration; hence, the efficacy of long term use is unclear. Longer and larger studies are also required to demonstrate the patient populations most likely to benefit from this technology.[88,89,110,111] The writing group conferred to device-guided breathing a Class IIA, Level of Evidence B recommendation for BP-lowering efficacy. Device-guided breathing is reasonable to perform in clinical practice to reduce BP. Should additional studies in larger and broader populations corroborate its effectiveness thus far demonstrated, it is conceivable that this technique may merit even stronger recommendations in the future.”

Please note: American Heart Association does not specifically recommend or endorse use of any products or brands.